In vitro inhibitory activities of magnolol against&lt;em&gt; Candida&lt;/em&gt; spp.

Zhou, Peiru; Fu, Jingzhu; Hua, Hong; Liu, Xiaosong

doi:10.2147/dddt.s146529

Cited by 17 publications

(18 citation statements)

References 46 publications

(54 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This result is consistent with the inhibitory concentration of magnolol on the biofilm formation of C. albicans in a previous study (Zhou et al, 2017).…”

Section: Synergistic Antifungal Activity Of Magnoliae Cortex and Syzygii Flos Extractsupporting

confidence: 93%

Synergistic Antifungal Activity of Magnoliae Cortex and Syzyii Flos against Candida albicans

Yoon¹

2021

Journal of the Korean Wood Science and Technology

View full text Add to dashboard Cite

Candida albicans is a dermal fungus of the human body that is known to cause oral candidiasis, vaginal candidiasis, and bloodstream infections in immunocompromised people or in certain environmental conditions. As cases of strains resistant to antifungal agents in C. albicans have been reported, studies using plant materials as safe antifungal agents are being actively conducted. In this study, a total of 17 edible plant extracts showed antifungal activity against C. albicans as a result of evaluating a 280-plant extract library using paper disk diffusion method. Among them, the four extracts with the strongest antifungal activity (Cinnamomi Cortex, Cinnamomi Ramulus, Magnoliae Cortex, and Syzygii Flos) were selected and evaluated for synergistic antifungal activity against C. albicans. The combination of Magnoliae Cortex and Syzygii Flos showed a synergistic activity. The antifungal activity was evaluated based on the concentrations of magnolol and eugenol, the respective components of Magnoliae Cortex and Syzygii Flos. Magnolol and eugenol showed synergistic antifungal activities at the concentration ratio of 1:25 -1:61. The antifungal activity of these two compounds contributes 28 to 48% to the synergistic antifungal activity of the combination of Magnoliae Cortex and Syzygii Flos extract. In this study, we propose that a combination of Magnoliae Cortex and Syzygii Flos can effectively inhibit the growth of C. albicans and that magnolol and eugenol are the responsible inhibitory compounds.

show abstract

“…This result is consistent with the inhibitory concentration of magnolol on the biofilm formation of C. albicans in a previous study (Zhou et al, 2017).…”

Section: Synergistic Antifungal Activity Of Magnoliae Cortex and Syzygii Flos Extractsupporting

confidence: 93%

Synergistic Antifungal Activity of Magnoliae Cortex and Syzyii Flos against Candida albicans

Yoon¹

2021

Journal of the Korean Wood Science and Technology

View full text Add to dashboard Cite

show abstract

“…30 Our previous research showed that the minimum fluconazole concentration required to inhibit Candida biofilms was 4-500 times higher than the MIC for planktonic cells. 37 In the present study, we found that the berberine concentration that significantly reduced the biofilm activity of C. albicans, C. krusei, and C. glabrata was only 4-32 times higher than the MIC for Candida cells in planktonic condition (Table 1; Figure 3). Hence, our results, to some extent, confirmed that berberine had more potent inhibitory effects against Candida biofilms than fluconazole.…”

Section: Discussionmentioning

confidence: 46%

<p>In vitro Antifungal Effects of Berberine Against<em> Candida</em> spp. In Planktonic and Biofilm Conditions</p>

Xie¹,

Liu²,

Zhou³

2020

DDDT

Self Cite

View full text Add to dashboard Cite

Purpose: Antifungal resistance associated with the extensive use of antifungals and biofilm formation presents major clinical challenges. Thus, new therapeutic strategies for fungal infections are urgently required. This study aimed to evaluate the in vitro antifungal effects of the natural bioactive alkaloid berberine against Candida spp. in planktonic and biofilm conditions. Methods: Using the CLSI M27-A3 reference method for broth dilution antifungal susceptibility testing of yeasts, the MICs for five standard strains comprised of Candida albicans (ATCC 10231, ATCC 90028), Candida krusei (ATCC 6258), Candida glabrata (ATCC 90030), Candida dubliniensis (MYA 646), and six clinical isolates (CLC1-CLC6) were tested. The 2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) reduction assay was used to evaluate the inhibitory effects of berberine against Candida biofilms. The optical density value at 490 nm was measured and illustrated using concentrationabsorbance curves. Finally, the effects were quantified by confocal laser scanning microscopy (CLSM), and 3-dimensional reconstruction was performed. The viability inhibition rates, biofilm formation, and thickness decrease rates were tested and analyzed using independentsamples t-test. The differences among the five Candida strains were analyzed using one way ANOVA. Results: The MICs for the five standard strains described above were 80, 160, 10, 20, and 40 μg/ mL, respectively, which was similar to that of the clinical isolates, suggesting the stable, broadspectrum antifungal activity of berberine. Berberine exerted concentration-dependent inhibitory effects against Candida biofilms, which were enhanced with the maturation of Candida biofilms. Berberine decreased the viability of Candida biofilms, with inhibition rates by CLSM ranging from 19.89 ± 0.57% to 96.93 ± 1.37%. Following 3-dimensional reconstruction, the biofilms of the berberine-treated group displayed a poorly developed architecture, and the biofilm thickness decrease rates ranged from 15.49 ± 8.45% to 30.30 ± 15.48%. Conclusion: Berberine exhibited significant antifungal activity in Candida spp. The results provide a useful reference for multiple Candida infections and biofilm infections associated with antifungal resistance. Therefore, berberine might have novel therapeutic potential as an antifungal agent or a major active component of antifungal drugs.

show abstract

“…Magnolol 1 interacts with ergosterol present in the cell membrane, inducing a partial disruption of the structure, but its mechanism of action is likely to differ from that of other inhibitors of sterol biosynthesis as it has proven effective also on fluconazole-resistant Candida spp. isolates [38]. Cell wall components such as β-1,3-glucans were proposed as potential target of magnolol, similarly to fungicides of the echinocandin family [39].…”

Section: Discussionmentioning

confidence: 99%

Honokiol, magnolol and its monoacetyl derivative show strong anti-fungal effect on Fusarium isolates of clinical relevance

et al. 2019

View full text Add to dashboard Cite

The antifungal activity of magnolol and honokiol, two naturally occurring hydroxylated biphenyls, and of their synthetic derivatives was evaluated on a collection of representative isolates of Fusarium oxysporum , F . solani and F . verticillioides of clinical and ecological concern. The tested compounds were proposed as a ‘natural’ alternative to conventional fungicides, even though a larger range of concentrations (5–400 μg/ml) was applied. The activity of magnolol and honokiol was compared with that of terbinafine (0.1–10 μg/ml), and fluconazole (1–50 μg/ml), two fungicides widely used in treating fungal infections on humans. Magnolol showed similar fungicidal activity compared to fluconazole, whereas honokiol was more effective in inhibiting mycelium growth compared to this fungicide on all tested clinical Fusarium spp. isolates. Compared to terbinafine, honokiol showed similar antifungal activity when tested on clinical F . solani isolates, whereas magnolol was less effective at all selected concentrations (5–400 μg/ml). The different position of the phenol-OH group, as well as its protection, explain different in vitro activities between magnolol, honokiol, and their derivatives. Furthermore, magnolol showed mycelium dry weight reduction at a concentration of 0.5 mM when tested on a set of agricultural isolates of Fusaria , leading to complete inhibition of some of them. Magnolol and honokiol are proposed as efficient and safe candidates for treating clinically relevant Fusaria .

show abstract

In vitro inhibitory activities of magnolol against<em> Candida</em> spp.

Cited by 17 publications

References 46 publications

Synergistic Antifungal Activity of Magnoliae Cortex and Syzyii Flos against Candida albicans

Synergistic Antifungal Activity of Magnoliae Cortex and Syzyii Flos against Candida albicans

<p>In vitro Antifungal Effects of Berberine Against<em> Candida</em> spp. In Planktonic and Biofilm Conditions</p>

Honokiol, magnolol and its monoacetyl derivative show strong anti-fungal effect on Fusarium isolates of clinical relevance

Contact Info

Product

Resources

About